Novartis’ former chief medical officer John Tsai has returned to a senior position in biopharma, taking the role of chief executive of UK start-up Forcefield Therapeutics.
This week saw two $250 million-plus initial public offering (IPO) filings for Neumora Therapeutics and RayzeBio, plus a record third-round financing for Generate Biomedici
This week saw a series of big-ticket funding rounds for biotech companies, with Apollo Therapeutics and Nimbus Therapeutics both pulling in upwards of $200 million, in a p
Despite the economic downturn, UK life sciences companies raised a healthy £382 million ($486 million) in new financing in the second quarter of the year, with venture cap
Anglo-Swiss life sciences investment company Medicxi has raised $400 million for its fourth fund, which will focus on supporting 'asset-centric' companies at all stages of
Novartis’ former chief medical officer John Tsai has returned to a senior position in biopharma, taking the role of chief executive of UK start-up Forcefield Therapeutics.
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho